AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400255-T1: [Translated] COMPOSITION OR KIT OF PELLETS FOR PREPARING CHINESE MEDICINAL TEAS AND METHOD FOR PRODUCING

Pellets (A) comprise an extract of a starting material (of vegetable, animal or mineral origin) for Chinese medicinal tea (CMT), contained in a matrix including hydrophilic macromolecules as structure-former (SF).  Independent claims are included for: (1) An 'instant' CMT preparation comprising the pellets (A) in lyophilized form;  (2) Assemblies or kits of pellets (A) comprising the same type of matrices containing at least two (preferably at least four) different extracts;  (3) A method for producing CMT, by separately boiling individual CMT starting materials, treating the obtained decoctions with SFs, forming pellets, lyophilizing and dissolving different types of pellets in water; and  (4) Production of CMTs in instant form, by forming a decoction from a CMT starting material, dissolving and/or dispersing SF in the decoction (preferably after removal of solids, especially by filtration), freezing the mixture by dropwise addition to very cold cryogenic fluid and lyophilizing the obtained pellets; and  (5) Instant CMT's obtained by the method.
NSDUH 2023 Field Interviewer Manual

This detailed manual was used as a training guide for the Field Interviewers (FIs) who conducted the in-person 2023 National Survey on Drug Use and Health (NSDUH). It covers the information presented at the intensive training for new FIs. Although it is written for NSDUH FIs, researchers may find it helpful for learning about data collection challenges that could affect data quality. It also may be helpful for those designing their own field operations.The manual includes:An introduction to the survey;A guide to what is expected of FIs;Copies of materials that were mailed or given to respondents;FI instructions for locating sample dwelling units, contacting residents, obtaining participation, conducting the screening and interview, documenting their experiences; andQuality control and administrative procedures for FIs.
Compound 528965: Phenol, 4-(1-methylbutyl)-2-nitro

Chemical compound data from PubChem database. IUPAC Name: 2-nitro-4-pentan-2-ylphenol. Molecular Formula: C11H15NO3. Molecular Weight: 209.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526385: 1,6-Dibromo,2,3-dichloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,6-dibromo-2,3-dichlorodibenzo-p-dioxin. Molecular Formula: C12H4Br2Cl2O2. Molecular Weight: 410.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Health Barometer: Wyoming, 2014

This is a behavioral health report for the state of Wyoming. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
New York City - 5 Boros

Data tables consisting of Excel files with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011, for drug-related emergency department visits in New York City (5 boroughs). Tables are provided for 10 topics (\"analytic categories\") which are defined in the \"Guide to Drug Abuse Warning Trend Tables,\" a separate document.   Each table includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology. Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Patent AT-E399856-T1: [Translated] NEW THERMOPHILES POLYMERASE III HOLOENZYME

Chemical patent from PubChem database. Patent Number: AT-E399856-T1. Title: Sustained Release Formulation. Filing Date: 1990-10-05. Inventors: Garcia, Maria, Miller, Thomas. Abstract: A sustained release formulation is provided, designed to maintain therapeutic drug levels over extended periods, reducing dosing frequency and improvi... IPC Classifications: C07D, A61K, A61P. This patent covers 12 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Monoarticular antigen-induced arthritis leads to pronounced bilateral upregulation of the expression of neurokinin 1 and bradykinin 2 receptors in dorsal root ganglion neurons of rats

This study describes the upregulation of neurokinin 1 and bradykinin 2 receptors in dorsal root ganglion (DRG) neurons in the course of antigen-induced arthritis (AIA) in the rat knee. In the acute phase of AIA, which was characterized by pronounced hyperalgesia, there was a substantial bilateral increase in the proportion of lumbar DRG neurons that express neurokinin 1 receptors (activated by substance P) and bradykinin 2 receptors. In the chronic phase the upregulation of bradykinin 2 receptors persisted on the side of inflammation. The increase in the receptor expression is relevant for the generation of acute and chronic inflammatory pain.
CCWIS Technical Assistance and Review Process

This webinar described the Comprehensive Child Welfare Information System (CCWIS) Technical Assistance Review Process. It began with an overview of the lessons learned from the Statewide Automated Child Welfare Information System (SACWIS) review process. The presentation described the iterative review process and it explains the use of self-assessment tools. As of this presentation, some self-assessment tools were available for public comment and others were in development.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526267: 1,3,4,7-Tetrabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,3,4,7-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526462: Ethyl perfluorohexanoate

Chemical compound data from PubChem database. IUPAC Name: ethyl 2,2,3,3,4,4,5,5,6,6,6-undecafluorohexanoate. Molecular Formula: C8H5F11O2. Molecular Weight: 342.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Information Memorandum (IM-09-02)

This Information Memorandum (IM) provides information on the Fostering Connections to Success and Increasing Adoptions Act of 2008 (Public Law (P.L.) 110-351); automation requirements and options for Tribes operating a title IV-E program pursuant to section 479B of the Social Security Act.

Metadata-only record linking to the original dataset. Open original dataset below.
Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma
		  concentrations at different SOFA scores during the course of sepsis and
		  MODS

Objectives:
          The relation of procalcitonin (PCT) plasma concentrations compared
				with C-reactive protein (CRP) was analyzed in patients with different severity
				of multiple organ dysfunction syndrome (MODS) and systemic inflammation.
        
        
          Patients and methods:
          PCT, CRP, the sepsis-related organ failure assessment (SOFA)
				score, the Acute Physiology, Age, Chronic Health Evaluation (APACHE) II score
				and survival were evaluated in 40 patients with systemic inflammation and
				consecutive MODS over a period of 15 days.
        
        
          Results:
          Higher SOFA score levels were associated with significantly higher
				PCT plasma concentrations (SOFA 7-12: PCT 2.62 ng/ml, SOFA 19-24: PCT
				15.22 ng/ml) (median), whereas CRP was elevated irrespective of the scores
				observed (SOFT 7-12: CRP 131 mg/l, SOFT 19-24: CRP 135 mg/l). PCT of
				non-surviving patients was initially not different from that of survivors but
				significantly increased after the fourth day following onset of the disease,
				whereas CRP was not different between both groups throughout the whole
				observation period.
        
        
          Conclusions:
          Measurement of PCT concentrations during multiple organ
				dysfunction syndrome provides more information about the severity and the
				course of the disease than that of CRP. Regarding the strong association of PCT
				and the respective score systems in future studies we recommend evaluation also
				of the severity of inflammation and MODS when PCT concentrations were compared
				between different types of disease.
Public Health Services- Chicago Primary Care Community Health Centers

Locations and contact information for Chicago primary care community health clinics (including all federally qualified health centers and similar community health centers that provide primary care and are open to the general community).  Additional information can be found at: http://j.mp/QfZ7SP

CDPH anticipates that this list will be used in the following ways: 1) by residents who are in need of 
assistance in finding a primary care physician and clinic near their homes; 2) by social service and 
public sector service providers that want to link their consumers to primary care near their homes; 3) 
by health system and public health researchers who are interested in Chicago’s primary care and 
safety net provider landscape. 
 
Clinics were excluded from this list if a) it is not specifically in their mission to care for underserved 
populations or b) if clinic services are only available to a narrowly defined population. 
 
Disclaimers: This list is intended to be a working document of primary care clinics for underserved 
populations in Chicago. If you believe an entry on this list to be outdated, misrepresented, or 
otherwise in error, please contact healthychicago@cityofchicago.org.
Compound 527375: 20,24-Dimethyl-nonacosyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 21,25-dimethyltriacontanenitrile. Molecular Formula: C32H63N. Molecular Weight: 461.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399707-T1: [Translated] ARRANGEMENT OF AN ACOUSTIC ARRAY WITH A SOUND VELOCITY METER

The positioning system (50) attaches to the lifting wire (42) and comprises a main module (51) and a counter module (52), each provided with thrusters (56) to control the positioning of an attached load. An attached processing system takes input from an acoustic source and a sound velocity meter, to take account of acoustic rays bending as velocity changes with depth, on the apparatus to control the thrusters and position the load at its required underwater position : Independent claims are also included for the following: (a) A processing arrangement arranged to drive an apparatus for deploying an object to an underwater target position; ( A vessel provided with a processing arrangement arranged to drive an apparatus for deploying an object to an underwater target position; ( A method of driving a processing arrangement arranged to drive an apparatus for deploying an object to an underwater target position; ( A computer program for carrying out a method of driving a processing arrangement arranged to drive an apparatus for deploying an object to an underwater target position.
Cultured Kaposi's sarcoma tumor cells exhibit a chemokine receptor repertoire that does not allow infection by HIV-1

Background
          HIV-1 is known to play a critical role in the pathogenesis of AIDS-associated Kaposi's sarcoma (KS). However, it remains controversial whether KS cells are target cells for HIV infection. The aim of this study was to investigate the expression of chemokine receptors in KS cell cultures and to determine whether these cells can be infected by HIV-1.
        
        
          Material and Methods
          KS-derived cells and KS-Y1 cells were investigated using RT-PCR for the expression of CD4, CCR3, CCR5, CCR8 and CXCR4 mRNA. HIV infectivity of these cells was determined by p24 antigen and HIV-1 RNA production, as well as by HIV-1 DNA integration.
        
        
          Results and Discussion
          With the exception of CCR8 which is expressed by KS-derived spindle cell cultures but not by KS-Y1 cells, unstimulated KS cells express no significant levels of CD4, CCR3, CCR5 or CXCR4 mRNA. HIV infectivity assays showed that KS cells were unpermissive to HTLVIIIB and JRFL strains. Although the expression of CXCR4 mRNA could be upregulated by interleukin-1β, stimulation of KS cells by this cytokine did not allow infection by HIV-1.
        
        
          Conclusions
          This shows that KS cells exhibit a chemokine receptor repertoire that does not allow infection by HIV-1. Other cell types making up KS lesions, such as inflammatory cells, are likely to represent the source of HIV-1 products cooperating to promote KS development and progression.
Compound 530482: 5-Chlorovaleric acid, 2-(1-adamantyl)ethyl ester

Chemical compound data from PubChem database. IUPAC Name: 2-(1-adamantyl)ethyl 5-chloropentanoate. Molecular Formula: C17H27ClO2. Molecular Weight: 298.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Imiquimod for the treatment of genital warts: a quantitative systematic review

Objective
          To review published randomised controlled trials to assess the benefit and harm of imiquimod in the treatment of external genital warts.
        
        
          Data sources
          MEDLINE (1966 - December 2000), Cochrane Library (Issue 3, 2000) and PubMed (December 15, 2000), review articles and reference lists.
        
        
          Review methods
          Included studies had to be randomised trials of imiquimod, to be full published papers, and to have a comparison group. Quality of trial reporting was assessed. Relative benefit and number needed to treat were calculated for the main outcomes of wart clearance at the end of therapy, of at least 50% reduction in wart area, and of complete clearance at the end of treatment and no recurrence of warts during a follow-up period, as well as for adverse effect withdrawal or lack of efficacy withdrawal.
        
        
          Results
          There were six trials, all with quality scores of 3 (out of 5) or greater. In five trials with HIV-negative patients complete clearance of warts at the end of treatment occurred in 51% of patients treated with imiquimod 2% or 5% cream and 6% of placebo treated patients. The number needed to treat was 2.2 (95% confidence interval 2.0 to 2.6). In four trials at least 50% wart area reduction occurred with 72% of patients treated with imiquimod 5% cream and 20% of placebo treated patients. The number needed to treat was 1.9 (1.7 to 2.2). In three trials complete clearance of warts at the end of treatment plus no recurrence occurred in 37% of patients treated with imiquimod 5% cream and 4% of those treated with placebo. The number needed to treat was 3.0 (2.5 to 3.8). Adverse event withdrawal was rare and no more likely with imiquimod than with placebo. Imiquimod was not effective in one trial in HIV-positive patients.
        
        
          Conclusion
          The evidence base for imiquimod in treating genital warts is of high quality and the necessary size from which to draw useful conclusions. Imiquimod is effective in home application, though not in patients with HIV infection with the evidence presently available.
Plan ID Crosswalk PUF - PY2021

The Plan ID Crosswalk PUF (CW-PUF) is one of the files that make up the Marketplace PUF. The purpose of the CW-PUF is to map QHPs and SADPs offered through the Marketplaces in 2020 to plans that will be offered through the Marketplaces in 2021. These data either originate from the Plan Crosswalk template (i.e., template field), an Excel-based form used by issuers to describe their plans in the QHP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).This data dictionary describes the variables contained in the CW-PUF. Each record relates to a mapping between a plan offered in 2020 and a plan offered in 2021 at the county or county-zip code level.
Patent AT-E400111-T1: [Translated] TRAFFIC FLOW OPTIMIZATION SYSTEM

A method of calculating data traffic flow in a communications network, the communications network comprising a plurality of nodes including a plurality of source nodes and a plurality of destination nodes, the nodes being connected to one another by links, the method comprising: (a) obtaining data traffic flow measurements through said nodes and links as input data; (b) correcting said input data if inconsistencies are detected; (c) calculating upper and lower bounds of data traffic flow from a selected one of the plurality of source nodes to a selected one of the plurality of destination nodes using the corrected input data.
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics

Background
          PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option.
        
        
          Methods
          The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition.
        
        
          Results
          In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0–9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women).
        
        
          Conclusions
          Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.
Fibroblast biology: Signals targeting the synovial fibroblast in arthritis

Fibroblast-like cells in the synovial lining (type B lining cells), stroma and pannus tissue are targeted by many signals, such as the following: ligands binding to cell surface receptors; lipid soluble, small molecular weight mediators (eg nitric oxide [NO], prostaglandins, carbon monoxide); extracellular matrix (ECM)-cell interactions; and direct cell-cell contacts, including gap junctional intercellular communication. Joints are subjected to cyclic mechanical loading and shear forces. Adherence and mechanical forces affect fibroblasts via the ECM (including the hyaluronan fluid phase matrix) and the pericellular matrix (eg extracellular matrix metalloproteinase inducer [EMMPRIN]) matrices, thus modulating fibroblast migration, adherence, proliferation, programmed cell death (including anoikis), synthesis or degradation of ECM, and production of various cytokines and other mediators [1]. Aggressive, transformed or transfected mesenchymal cells containing proto-oncogenes can act in the absence of lymphocytes, but whether these cells represent regressed fibroblasts, chondrocytes or bone marrow stem cells is unclear.
#DDOD Use Case: Historical Structured Product Labels for FDA-Approved Drugs

<p>SUMMARY</p>
<p>DDOD use case to request access historical label revisions of FDA-approved drugs.</p>
<p>WHAT IS A USE CASE?</p>
<p>A “Use Case” is a request that was made by the user community because there were no available datasets that met their particular needs.  If this use case is similar to your needs, we ask that you add your own requirements to the specifications section.</p>
<p>The concept of a use case falls within the <a href="http://hhs.ddod.us ">Demand-Driven Open Data</a> (DDOD) program and gives you a formalized way to identify what data you need.  It’s for anyone in industry, research, media, nonprofits or other government agencies.  Each request becomes a DDOD use case, so that it can be prioritized and worked on.</p>
<p>Use Cases also provide a wealth of insights about existing alternative datasets and tips for interpreting and manipulating data for specific purposes.</p>
<p>PURPOSE</p>
<p>Drug manufacturers and distributions submit documentation about their products to FDA in Structured Product Labeling (SPL) that is available via openFDA. However, the approved labeling is a "living document" that is updated over time to reflect increased knowledge about the safety and effectiveness of the drug. The real-time nature of the labeling information makes it difficult to track the historical changes to a product's label and indications.</p>
<p>VALUE</p>
<p>The historical context of a product's label and indications is important in understanding how and why product labeling changes and in evaluating pharmaceutical market access.</p>
<p>USE CASE SPECIFICATIONS &amp; SOLUTION</p>
<p>Information about this use cases is maintained in a wiki: <a href="http://hhs.ddod.us/wiki/Use_Case_25:_History_for_structured_product_labels">http://hhs.ddod.us/wiki/Use_Case_25:_History_for_structured_product_labels</a></p>
<p>It serves as a knowledge base.</p>
<p>USE CASE DISCUSSION FORUM</p>
<p>All communications between Data Users, DDOD Administrators and Data Owners are logged as discussions within GitHub issues: <a href="https://github.com/demand-driven-open-data/ddod-intake/issues/25">https://github.com/demand-driven-open-data/ddod-intake/issues/25</a></p>
<p>It aims to provide complete transparency into the process and ensure the same message gets to all participants.</p>
<p>CASE STATUS</p>
<p>Closed via DailyMed, which has XML files of historical SPLs</p>
QHP Landscape Instructions PY2024 Individual Dental

The Dental Individual Market file of the QHP Landscape Files contains information on certified dental plans offered through an Exchange to consumers in the individual market. These plans are also known as Stand-alone Dental Plans (SADPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.